Publications by authors named "D J Dorey"
Article Synopsis
- Expanded analysis of predictors of confirmed virologic failure (CVF) in 1651 participants taking cabotegravir + rilpivirine long-acting (CAB + RPV LA) included data beyond 48 weeks and considered various demographic and viral factors.
- Results showed that 1.4% of participants experienced CVF, with risks increasing for those with mutations associated with rilpivirine resistance, specific HIV subtypes, and higher body mass index.
- The study concluded that having two or more of these baseline factors has a significant impact on the risk of CVF, indicating the importance of these factors in effectively managing treatment with CAB + RPV LA.
Article Synopsis
- There is a growing need for less frequent and more convenient HIV treatment options to alleviate issues like stigma and the burden of daily medication.
- The phase 3 ATLAS and FLAIR studies demonstrated that long-acting cabotegravir and rilpivirine, given every 4 weeks, is as effective as standard daily oral therapy in maintaining viral suppression in HIV-1 patients over 48 weeks.
- The FLAIR study reveals ongoing data and effectiveness of switching to long-acting treatments in virologically suppressed adults over a longer period of 96 weeks.
Objective: Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here, factors associated with virologic failure at Week 48 were evaluated post hoc.
Design And Methods: Data from 1039 adults naive to long-acting CAB+RPV were pooled in a multivariable analysis to examine the influence of baseline viral and participant factors, dosing regimen and drug concentrations on confirmed virologic failure (CVF) occurrence using a logistic regression model.
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (HIVTSQ) and acceptance (ACCEPT general domain), health status (SF-12), injection tolerability/acceptance (PIN), and treatment preference. In pooled analyses, LA-treated patients (n = 591) demonstrated greater mean improvements from baseline than the CAR group (n = 591) in treatment satisfaction (Week 44, + 3.
View Article and Find Full Text PDFBackground: Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection.
Methods: We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine. Participants who had an HIV-1 RNA level of less than 50 copies per milliliter after 16 weeks were randomly assigned (1:1) to continue the current oral therapy or switch to oral cabotegravir plus rilpivirine for 1 month followed by monthly injections of long-acting cabotegravir plus rilpivirine.